Bristol-Myers scores a critical endorsement for its embattled Celgene merger

Bristol-Myers Squibb, fighting off investor protests of its planned merger with Celgene, has won over the most influential advisers on Wall Street, improving the company’s odds of pulling off the $74 billion deal.